Literature DB >> 11921459

Mucociliary clearance in cystic fibrosis.

Michael Robinson1, Peter T B Bye.   

Abstract

Abnormal mucociliary clearance (MCC) is one of the central hypotheses for the development of lung disease in patients with cystic fibrosis (CF). However, attempts to demonstrate this decrease of MCC in vivo have proved to be somewhat less definitive, with the evidence barely favoring impaired clearance. Any apparent disparities are most likely due to the variety of methodologies used by different laboratories to measure MCC. The limitations of the various methodologies are examined in this review, in an attempt to better facilitate comparison of results. A number of physical and pharmacological therapies have been developed to promote mucus clearance from the CF airway. A summary of the results of interventional studies utilizing the measurement of MCC as an outcome measure is presented. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11921459     DOI: 10.1002/ppul.10079

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  44 in total

1.  Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition.

Authors:  Annika B M Åstrand; Martin Hemmerling; James Root; Cecilia Wingren; Jelena Pesic; Edvin Johansson; Alaina L Garland; Arunava Ghosh; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

Review 2.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

3.  Repurposing tromethamine as inhaled therapy to treat CF airway disease.

Authors:  Mahmoud H Abou Alaiwa; Janice L Launspach; Kelsey A Sheets; Jade A Rivera; Nicholas D Gansemer; Peter J Taft; Peter S Thorne; Michael J Welsh; David A Stoltz; Joseph Zabner
Journal:  JCI Insight       Date:  2016-06-02

4.  Restoration of mucociliary transport in the fluid-depleted trachea by surface-active instillates.

Authors:  Stephen T Ballard; James C Parker; Charles R Hamm
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-15       Impact factor: 6.914

Review 5.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

6.  Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.

Authors:  Michael D Kim; Nathalie Baumlin; Makoto Yoshida; Deepika Polineni; Sebastian F Salathe; Joseph K David; Charles A Peloquin; Adam Wanner; John S Dennis; Juliette Sailland; Philip Whitney; Frank T Horrigan; Juan R Sabater; William M Abraham; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

7.  Gel-forming mucins form distinct morphologic structures in airways.

Authors:  Lynda S Ostedgaard; Thomas O Moninger; James D McMenimen; Nicholas M Sawin; Connor P Parker; Ian M Thornell; Linda S Powers; Nicholas D Gansemer; Drake C Bouzek; Daniel P Cook; David K Meyerholz; Mahmoud H Abou Alaiwa; David A Stoltz; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

8.  Acidic Submucosal Gland pH and Elevated Protein Concentration Produce Abnormal Cystic Fibrosis Mucus.

Authors:  Yuliang Xie; Lin Lu; Xiao Xiao Tang; Thomas O Moninger; Tony Jun Huang; David A Stoltz; Michael J Welsh
Journal:  Dev Cell       Date:  2020-07-29       Impact factor: 12.270

9.  Cystic fibrosis transmembrane conductance regulator function, not TAS2R38 gene haplotypes, predict sinus surgery in children and young adults with cystic fibrosis.

Authors:  Nicholas M Dalesio; Melis A Aksit; Kwangmi Ahn; Karen S Raraigh; Joseph M Collaco; Sharon McGrath-Morrow; Pamela L Zeitlin; Steven S An; Garry R Cutting
Journal:  Int Forum Allergy Rhinol       Date:  2020-04-13       Impact factor: 3.858

10.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.